JP6008937B2 - 1−(3−シアノ−1−イソプロピル−インドール−5−イル)ピラゾール−4−カルボン酸の結晶形とその製造方法 - Google Patents
1−(3−シアノ−1−イソプロピル−インドール−5−イル)ピラゾール−4−カルボン酸の結晶形とその製造方法 Download PDFInfo
- Publication number
- JP6008937B2 JP6008937B2 JP2014503602A JP2014503602A JP6008937B2 JP 6008937 B2 JP6008937 B2 JP 6008937B2 JP 2014503602 A JP2014503602 A JP 2014503602A JP 2014503602 A JP2014503602 A JP 2014503602A JP 6008937 B2 JP6008937 B2 JP 6008937B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- crystalline form
- producing
- crystal form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2011-0031490 | 2011-04-06 | ||
KR20110031490 | 2011-04-06 | ||
PCT/KR2012/002575 WO2012138147A2 (fr) | 2011-04-06 | 2012-04-05 | Forme cristalline de l'acide 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylique et son procédé de préparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014510133A JP2014510133A (ja) | 2014-04-24 |
JP6008937B2 true JP6008937B2 (ja) | 2016-10-19 |
Family
ID=46969691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014503602A Active JP6008937B2 (ja) | 2011-04-06 | 2012-04-05 | 1−(3−シアノ−1−イソプロピル−インドール−5−イル)ピラゾール−4−カルボン酸の結晶形とその製造方法 |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP6008937B2 (fr) |
KR (1) | KR101424013B1 (fr) |
CN (1) | CN103459381B (fr) |
TW (1) | TWI548630B (fr) |
WO (1) | WO2012138147A2 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106008488B (zh) * | 2016-05-20 | 2018-10-30 | 广东东阳光药业有限公司 | 氰基吲哚类衍生物及其制备方法和用途 |
CN106045898B (zh) * | 2016-06-28 | 2019-05-24 | 广东东阳光药业有限公司 | 一种吲哚类化合物及其制备方法和用途 |
AU2017364804A1 (en) * | 2016-11-28 | 2019-05-02 | Teijin Pharma Limited | Therapeutic drug or prophylactic drug for diabetic nephropathy |
CN116456979A (zh) * | 2020-11-04 | 2023-07-18 | 株式会社Lg化学 | 1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸结晶粒子的制备方法以及包含其的药物组合物 |
JP2023551712A (ja) | 2020-12-01 | 2023-12-12 | エルジー・ケム・リミテッド | 1-(3-シアノ-1-イソプロピル-インドール-5-イル)ピラゾール-4-カルボン酸を含む安定した経口用製剤 |
CN116528853A (zh) | 2020-12-01 | 2023-08-01 | 株式会社Lg化学 | 包含1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的口服制剂及其制备方法 |
PE20240764A1 (es) | 2021-04-16 | 2024-04-17 | Lg Chemical Ltd | Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico |
KR20220147532A (ko) * | 2021-04-27 | 2022-11-03 | 주식회사 엘지화학 | 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 |
BR112023022484A2 (pt) * | 2021-04-29 | 2024-01-09 | Jiangsu Atom Bioscience And Pharmaceutical Co Ltd | Composto na fórmula geral (i) ou um sal farmaceuticamente aceitável deste, composição farmacêutica e uso do composto ou sais farmaceuticamente aceitáveis deste |
CN117425477A (zh) | 2021-06-15 | 2024-01-19 | 株式会社Lg化学 | 包含1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的药物组合物 |
AR126164A1 (es) | 2021-06-17 | 2023-09-27 | Lg Chemical Ltd | Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico |
TWI822151B (zh) * | 2021-07-02 | 2023-11-11 | 南韓商Lg化學股份有限公司 | 製備黃嘌呤氧化酶抑制劑的方法 |
CN116836154A (zh) * | 2022-04-27 | 2023-10-03 | 江苏新元素医药科技有限公司 | 可用于痛风的化合物 |
CN116715633A (zh) * | 2022-04-27 | 2023-09-08 | 江苏新元素医药科技有限公司 | 可用于降尿酸的化合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19602505A1 (de) * | 1996-01-25 | 1997-07-31 | Merck Patent Gmbh | 1-(Pyrazol-4-Indol-3-yl)-Piperidine |
WO2007113647A1 (fr) * | 2006-04-04 | 2007-10-11 | Pfizer Products Inc. | Formes polymorphes de (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-méthyl-1h-pyrazol-4υl)-1-oxo-2,6-dihydro-1h-[1,2]diazépino[4,5,6-cd]indol-8-yl)acétamide |
BRPI0810524B8 (pt) * | 2007-04-11 | 2021-05-25 | Kissei Pharmaceutical | derivado de (aza)indol, inibidor de xantina oxidase e composição farmacêutica compreendendo o dito derivado |
WO2008126901A1 (fr) * | 2007-04-11 | 2008-10-23 | Kissei Pharmaceutical Co., Ltd. | Composé hétérocyclique contenant de l'azote et composition pharmaceutique le contenant |
TWI423962B (zh) * | 2009-10-07 | 2014-01-21 | Lg Life Sciences Ltd | 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物 |
-
2012
- 2012-03-30 TW TW101111308A patent/TWI548630B/zh active
- 2012-04-05 WO PCT/KR2012/002575 patent/WO2012138147A2/fr active Application Filing
- 2012-04-05 KR KR1020120035349A patent/KR101424013B1/ko active IP Right Grant
- 2012-04-05 CN CN201280016696.6A patent/CN103459381B/zh active Active
- 2012-04-05 JP JP2014503602A patent/JP6008937B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
CN103459381A (zh) | 2013-12-18 |
WO2012138147A3 (fr) | 2012-11-29 |
WO2012138147A2 (fr) | 2012-10-11 |
KR101424013B1 (ko) | 2014-08-18 |
TWI548630B (zh) | 2016-09-11 |
JP2014510133A (ja) | 2014-04-24 |
TW201245182A (en) | 2012-11-16 |
KR20120114174A (ko) | 2012-10-16 |
CN103459381B (zh) | 2015-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6008937B2 (ja) | 1−(3−シアノ−1−イソプロピル−インドール−5−イル)ピラゾール−4−カルボン酸の結晶形とその製造方法 | |
JP3927175B2 (ja) | N−置換ヒドロキシピリミジノンカルボキサミド系hivインテグラーゼ阻害薬 | |
JP2020518662A (ja) | 化合物の結晶多形、その製造方法及び用途 | |
TWI617554B (zh) | 組織胺h受體之苯并咪唑-2-基嘧啶調控劑 | |
WO2007107772A1 (fr) | Sels présentant une activité crth2 antagoniste | |
JP6240164B2 (ja) | ピロール誘導体の結晶及びその製造方法 | |
JP2009539881A (ja) | Dp−2アンタゴニストとしての置換フェニル酢酸 | |
JP2014505107A (ja) | 過誤腫性腫瘍細胞を阻害する方法 | |
WO2016031987A1 (fr) | Dérivé de pyrimidone ayant une activité inhibitrice de l'autotaxine | |
WO2016054959A1 (fr) | Forme cristalline de bisulfate d'inhibiteur de jak et son procédé de préparation | |
JP2015522037A (ja) | ベムラフェニブコリン塩の固体形態 | |
JP2023071922A (ja) | 7h-ピロロ[2,3-d]ピリミジンjak-阻害剤 | |
CN107922385A (zh) | Cgrp受体拮抗剂 | |
CN111278808B (zh) | 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式 | |
US20200223861A1 (en) | Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione | |
WO2021236491A1 (fr) | Agents de dégradation de hdac dérivés de la benzoylhydrazide servant d'agents thérapeutiques permettant le traitement du cancer et d'autres maladies humaines | |
JP2023502675A (ja) | 核タンパク質阻害剤の結晶形及びその使用 | |
JPH03264579A (ja) | ピリミジン誘導体 | |
JP2011510967A (ja) | 新規複素環化合物 | |
WO2018068357A1 (fr) | Nouvel inhibiteur de protéine sirt2 et son utilisation pharmaceutique | |
JP5872105B2 (ja) | ピロリジン−3−イル酢酸誘導体の塩およびその結晶 | |
JP6078551B2 (ja) | 2−(2−メチルアミノ−ピリミジン−4−イル)−1h−インドール−5−カルボン酸[(s)−1−カルバモイル−2−(フェニル−ピリミジン−2−イル−アミノ)−エチル]−アミドの結晶形 | |
CN102666528B (zh) | 晶体cdc7 抑制剂盐 | |
TW200817392A (en) | Salt of morpholine compound | |
WO2019119481A1 (fr) | Inhibiteur de kinase dérivé de carbazole |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150402 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20151112 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20151117 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160209 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160316 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160816 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160913 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6008937 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |